SOST and osteogenesis imperfecta: The anti-sclerostin antibody, the only currently available drug approved for osteoporosis and in clinical trials for OI that enhances collagen deposition, does not specifically target collagen but, being an inhibitor of the WNT pathway, exerts an effect on other essential cellular functions, with potential serious side effects (47, 48).